 All investigators will be aware of study design and subject treatment during the single-blind phase of study. It is important that the subject remain blinded to the nature of treatment during all phases of study. The subjects will be treated at all times, as if they were on active treatment of nabilone. If any subject becomes aware of their treatment type during any phase of the study, their participation must be discontinued. 